- Email: [email protected]
Patterns of anemia during malaria
Accepted Manuscript Title: Patterns of anemia during malaria Author: St´ephane Jaur´eguiberry Papa Alioune Ndour Marc Thellier Eric Caumes Pierre Buffet PII: DOI: Reference:
S1201-9712(15)00008-9 http://dx.doi.org/doi:10.1016/j.ijid.2014.12.048 IJID 2241
To appear in:
International Journal of Infectious Diseases
Received date: Accepted date:
19-12-2014 25-12-2014
Please cite this article as: Jaur´eguiberry S, Ndour PA, Thellier M, Caumes E, Buffet P, Patterns of anemia during malaria, International Journal of Infectious Diseases (2015), http://dx.doi.org/10.1016/j.ijid.2014.12.048 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Letter to the editor Patterns of anemia during malaria
ip t
Stéphane Jauréguiberry,1, 2, 3 Papa Alioune Ndour,2 Marc Thellier,2, 3, 4 Eric Caumes,1 Pierre Buffet 2, 3, 4
Paris, F-75013, France
cr
1. AP-HP, Hôpital Pitié-Salpêtrière, Service des maladies infectieuses et médecine tropicale,
2. Centre d’Immunologie et des Maladies Infectieuses de Paris, CIMI-PARIS, U 1135
us
INSERM/UPMC Université Paris VI, Paris F-75005, France
3. Centre National de Référence du Paludisme-site Pitié Salpetrière, Paris, F-75013, France
an
4. AP-HP, Hôpital Pitié-Salpêtrière, Service de parasitologie-mycologie, Paris, F-75013, France
Word count: 340
Ac ce p
te
d
M
References: 6
Page 1 of 3
Dear Editor, We read with interest the article by Rehman et al. on post-artesunate hemolysis (PADH) (1). Hemolysis is indeed commonly associated with the class of artemisinin drugs when used for the treatment of severe malaria. Their review confirmed the high incidence of this adverse event related
ip t
to the mode of action of artemisinins and the physiological role of the spleen (2). As the authors wisely pointed out, delayed hemolysis should not jeopardize the deployment of artesunate as the
cr
first-line treatment of severe malaria worldwide. While PADH is indeed rarely (if ever) fatal, artesunate significantly reduces mortality as compared to quinine, markedly so in patients with
us
parasitemia greater than 10% on admission (3). Importantly, PADH has been further characterized by a pathophysiological study in travelers treated with artesunate for severe malaria (4). Early peak concentrations of circulating once-infected erythrocytes are predictive for the occurrence of PADH
an
and may therefore serve as a future candidate marker for PADH. Rehman et al. referred to different anemia patterns in their analysis of published reports. This definition was based on initial descriptions by Zoller et al. (5) and on a more refined definition proposed in a closed meeting
M
organized by the Medicine for Malaria Venture (MMV) in March 2013 in Vienna (http://www.mmv.org/sites/default/files/uploads/docs/events/2013/
d
InjectableArtesunateExpertGroupMeeting.pdf) (6) and later published in the above mentioned pathophysiological paper (4). Whereas initial reports were acknowledged in the article by
te
Rehman et al., the optimized nosological classification was not referenced in the manuscript. This omission is likely due to the disclosure in the MMV report (which became publicly available in 2013)
Ac ce p
of the then unpublished, optimized case definition proposed by our group, without precise referencing of the source of that particular set of information. Sharing unpublished results or concepts during subject-specific meetings, like the one efficiently organized by MMV in Vienna, is important as it allows the malaria community to adapt rapidly and efficiently to new problems with a public health impact. When reports of such meetings carefully acknowledge all respective contributions, this ultimately contributes to maintaining rich exchanges between attendees.
References
1. Rehman K, Lotsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. International
Page 2 of 3
Ac ce p
te
d
M
an
us
cr
ip t
journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2014; 29C: 268-273. 2. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, Turner GD, Mercereau-Puijalon O. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011; 117: 381-392. 3. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-725. 4. Jaureguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P, French Artesunate Working G. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124: 167-175. 5. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Morch K, Foroutan B, Suttorp N, Yurek S, Flick H. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17: 771-777. 6. MMV. Experts Group Meeting on delayed anaemia following treatment with injectable artesunate, Wien Austria. http://www.mmv.org/sites/default/files/uploads/docs/events/2013/InjectableArtesunateEx pertGroupMeeting.pdf; 2013.
Page 3 of 3
S1201-9712(15)00008-9 http://dx.doi.org/doi:10.1016/j.ijid.2014.12.048 IJID 2241
To appear in:
International Journal of Infectious Diseases
Received date: Accepted date:
19-12-2014 25-12-2014
Please cite this article as: Jaur´eguiberry S, Ndour PA, Thellier M, Caumes E, Buffet P, Patterns of anemia during malaria, International Journal of Infectious Diseases (2015), http://dx.doi.org/10.1016/j.ijid.2014.12.048 This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
Letter to the editor Patterns of anemia during malaria
ip t
Stéphane Jauréguiberry,1, 2, 3 Papa Alioune Ndour,2 Marc Thellier,2, 3, 4 Eric Caumes,1 Pierre Buffet 2, 3, 4
Paris, F-75013, France
cr
1. AP-HP, Hôpital Pitié-Salpêtrière, Service des maladies infectieuses et médecine tropicale,
2. Centre d’Immunologie et des Maladies Infectieuses de Paris, CIMI-PARIS, U 1135
us
INSERM/UPMC Université Paris VI, Paris F-75005, France
3. Centre National de Référence du Paludisme-site Pitié Salpetrière, Paris, F-75013, France
an
4. AP-HP, Hôpital Pitié-Salpêtrière, Service de parasitologie-mycologie, Paris, F-75013, France
Word count: 340
Ac ce p
te
d
M
References: 6
Page 1 of 3
Dear Editor, We read with interest the article by Rehman et al. on post-artesunate hemolysis (PADH) (1). Hemolysis is indeed commonly associated with the class of artemisinin drugs when used for the treatment of severe malaria. Their review confirmed the high incidence of this adverse event related
ip t
to the mode of action of artemisinins and the physiological role of the spleen (2). As the authors wisely pointed out, delayed hemolysis should not jeopardize the deployment of artesunate as the
cr
first-line treatment of severe malaria worldwide. While PADH is indeed rarely (if ever) fatal, artesunate significantly reduces mortality as compared to quinine, markedly so in patients with
us
parasitemia greater than 10% on admission (3). Importantly, PADH has been further characterized by a pathophysiological study in travelers treated with artesunate for severe malaria (4). Early peak concentrations of circulating once-infected erythrocytes are predictive for the occurrence of PADH
an
and may therefore serve as a future candidate marker for PADH. Rehman et al. referred to different anemia patterns in their analysis of published reports. This definition was based on initial descriptions by Zoller et al. (5) and on a more refined definition proposed in a closed meeting
M
organized by the Medicine for Malaria Venture (MMV) in March 2013 in Vienna (http://www.mmv.org/sites/default/files/uploads/docs/events/2013/
d
InjectableArtesunateExpertGroupMeeting.pdf) (6) and later published in the above mentioned pathophysiological paper (4). Whereas initial reports were acknowledged in the article by
te
Rehman et al., the optimized nosological classification was not referenced in the manuscript. This omission is likely due to the disclosure in the MMV report (which became publicly available in 2013)
Ac ce p
of the then unpublished, optimized case definition proposed by our group, without precise referencing of the source of that particular set of information. Sharing unpublished results or concepts during subject-specific meetings, like the one efficiently organized by MMV in Vienna, is important as it allows the malaria community to adapt rapidly and efficiently to new problems with a public health impact. When reports of such meetings carefully acknowledge all respective contributions, this ultimately contributes to maintaining rich exchanges between attendees.
References
1. Rehman K, Lotsch F, Kremsner PG, Ramharter M. Haemolysis associated with the treatment of malaria with artemisinin derivatives: a systematic review of current evidence. International
Page 2 of 3
Ac ce p
te
d
M
an
us
cr
ip t
journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases 2014; 29C: 268-273. 2. Buffet PA, Safeukui I, Deplaine G, Brousse V, Prendki V, Thellier M, Turner GD, Mercereau-Puijalon O. The pathogenesis of Plasmodium falciparum malaria in humans: insights from splenic physiology. Blood 2011; 117: 381-392. 3. Dondorp A, Nosten F, Stepniewska K, Day N, White N. Artesunate versus quinine for treatment of severe falciparum malaria: a randomised trial. Lancet 2005; 366: 717-725. 4. Jaureguiberry S, Ndour PA, Roussel C, Ader F, Safeukui I, Nguyen M, Biligui S, Ciceron L, Mouri O, Kendjo E, Bricaire F, Vray M, Angoulvant A, Mayaux J, Haldar K, Mazier D, Danis M, Caumes E, Thellier M, Buffet P, French Artesunate Working G. Postartesunate delayed hemolysis is a predictable event related to the lifesaving effect of artemisinins. Blood 2014; 124: 167-175. 5. Zoller T, Junghanss T, Kapaun A, Gjorup I, Richter J, Hugo-Persson M, Morch K, Foroutan B, Suttorp N, Yurek S, Flick H. Intravenous artesunate for severe malaria in travelers, Europe. Emerg Infect Dis 2011; 17: 771-777. 6. MMV. Experts Group Meeting on delayed anaemia following treatment with injectable artesunate, Wien Austria. http://www.mmv.org/sites/default/files/uploads/docs/events/2013/InjectableArtesunateEx pertGroupMeeting.pdf; 2013.
Page 3 of 3